New compositions of tissue-equivalent three-dimensional polymer gel dosimeters based on acrylamide (AAm), N-isopropylacrylamide (NIPAM), N-(Hydroxymethyl)acrylamide (NHMA), diacetone acrylamide (DAAM) and N-Vinylcaprolactam (NVCL) monomer with ethylene glycol co-solvent have been introduced in this invention for radiotherapy dosimetry. The dosimeter was irradiated with 6 and 15 MV linear accelerator at absorbed doses up to 10 Gy. The nuclear magnetic resonance (NMR) spin-spin relaxation rate (R.sub.2) for water proton surrounding polymer formation was used to investigate the degree of polymerization of the five gels. The effect of additives, dose rate, radiation energy, stability of the polymerization after irradiation, were investigated on the dose response of the gels.

The present invention provides a radioactive patch comprising a layer of a mixture of a radionuclide with a nonreactive adhesive agent coated thereon in the form of a tape, and a laminating layer, wherein the patch comprises, a high Z shielding layer placed on the opposing side of the patch away from the patient tissue, and comprising at least one of: lead, tungsten, iron, silver, gold, platinum, copper, brass; and wherein the patch comprises, a low Z shielding layer comprising at least one of: teflon, pma, pvc, lucite, boron carbide, graphite, carbon fiber, bakelite; and wherein the radionuclide comprises at least one of: Y-90, Ho-166, LU-166, I-125, PD-103, LU-166, or any combination thereof.

The present invention provides radioactive dermatological patch designed to topically treat cutaneous skin lesions in patient tissue. The radioactive dermatological patch includes a layer of a radionuclide with a nonreactive binding agent to form a treatment wafer. The treatment wafer is then placed within the radioactive dermatological patch. The radioactive dermatological patch includes a high Z distal shielding layer placed adjacent the side of treatment wafer away from the patient tissue. The distal shielding layer attenuating the energy of the radionuclide from the environment external to the patient. The patch further includes a high Z proximal patient shielding layer placed between the patient tissue and treatment wafer.

This invention relates to a ceramic module for assembly into a therapeutic device for treating a human or animal body with irradiation of far infrared radiation and low dose ionizing radiation based on radiation hormesis effect. More specifically, the invention relates to a ceramic module that simultaneously emits far infrared radiation within 3-16 μm wavelength spectrum and ionizing radiation at a specific dose rate in the range of 0.1-11 μSv/h (micro-Sieverts per hour). Said ceramic module may be used alone or serve as components of a therapeutic device for increasing physiologic performance, immune competence, health, and mean lifespan of human or animal.

Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165 (.sup.165Ho) and dysprosium-164 (.sup.164Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particles and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandage coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).

A prosthesis, radiation bolus, pre-surgical model, or burn mask formed using a rapid prototyping device, such as a three-dimensional printer. In some exemplary aspects, the prosthesis includes a scaffolding and a coating at least partially covering the scaffolding. Methods and systems for forming the prosthesis, radiation bolus, pre-surgical model, or burn mask are also provided.

A bandage having an electrospun sheet having a polyacrylonitrile nanofiber embedded with a carrier nanoparticle or a carrier particle, the carrier nanoparticle or carrier particle including an activatable nuclide selected from the group consisting of yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium-165, rhenium-185, rhenium-187, and combinations thereof. The bandage has a laminate enclosure, enclosing the electrospun sheet and the bandage has a distribution of the carrier nanoparticle or the carrier particle to emit a uniform radiation across the surface area of the bandage after neutron-activation.

Provided is a process of producing activated particles comprising .sup.188Re-isotopes and/or .sup.186Re-isotopes by irradiating non-volatile and water-insoluble starting particles comprising a rhenium compound with neutrons. Further provided is a process of producing corresponding non-volatile and water-insoluble starting particles. Further provided are respective starting particles and activated particles, respectively, and a composition comprising a plurality of activated particles. The activated particles, and the composition comprising same are suitable for use in radionuclide therapy, and for cosmetic applications.

A light emitting device array includes a substrate, a heat sink disposed on the substrate, at least two light emitting devices disposed on the heat sink and spaced apart from each other, a connector disposed on the light emitting device and configured to apply power, an insulating layer interposed between the heat sink and the connector, a fixing member configured to support a position of the light emitting device, on the light emitting device, and an adhesive layer provided on the fixing member to make contact with a skin.

A flexible brachytherapy device includes a bioresorbable carrier matrix structure comprising a plurality of radio-isotope particles and having opposite first and second surfaces. The bioresorbable carrier matrix structure degrades, when implanted at a wound site, at a rate such that the bioresorbable carrier matrix structure has a half-life that is longer than a half-life of the plurality of radio-isotope particles. A hydrophilic substrate located adjacent to the first surface of the bioresorbable carrier matrix structure degrades, when implanted at the wound site, at a rate faster than the bioresorbable carrier matrix structure. A hydrogel substrate located adjacent to the second surface of the bioresorbable carrier matrix structure shields radioactivity and degrades at a rate such that the hydrogel substrate has a half-life that is longer than the half-life of the plurality of radio-isotope particles.